Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected to show a rise in quarterly revenue when it reports results on March 30 (estimated) for the period ending December 31 2025
The Littleton Colorado-based company is expected to report a 74.4% increase in revenue to $6.448 million from $3.7 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 48 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vivos Therapeutics Inc is $5.50, about 378.3% above its last closing price of $1.15
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.52 | -0.51 | -0.49 | Beat | 3.9 |
Jun. 30 2025 | -0.38 | -0.38 | -0.55 | Missed | -42.9 |
Mar. 31 2025 | -0.40 | -0.40 | -0.45 | Missed | -12.5 |
Dec. 31 2024 | -0.39 | -0.28 | Beat | 29.1 | |
Sep. 30 2024 | -0.61 | -0.61 | -0.40 | Beat | 34.4 |
Jun. 30 2024 | -1.05 | -0.60 | Beat | 42.9 | |
Mar. 31 2024 | -1.17 | -1.17 | -1.63 | Missed | -38.7 |
Dec. 31 2023 | -1.75 | -1.90 | -3.05 | Missed | -60.1 |
This summary was machine generated March 27 at 21:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments